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Abstract
Marfan Syndrome is an autosomal dominant, genetically inherited connective tissue
disorder  which  primarily  affects  the  cardiovascular  system  but  can  also  have
systemic  manifestations.  First  described  in  1896,  Marfan  Syndrome  has  a
prevalence of around 1/5000 in the general population. It is becoming increasingly
common  to  see  patients  with  Marfan  Syndrome  in  a  clinical  setting  due  to  the
improved  care  of  patients  with  adult  congenital  heart  disease  and  general
improvement in survival. Mortality however remains high, largely due to the risk of
aortic  dissection as a result  of  the aortic  root  dilatation frequently  seen in  these
patients. Contemporary management therefore has been focused on imaging-based
surveillance to prevent these catastrophic events and intervene surgically in a timely
manner. However, it is increasingly recognised that some patients do suffer aortic
dissection below the expected threshold for surgical intervention. With this in mind,
there has been interest in the role of biomarkers as an adjunct to imaging in the care
of these patients. This article will provide an overview of the literature on potential
biomarkers studied so far in Marfan Syndrome as well as potential future directions.  
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Introduction
Marfan Syndrome – a multi-system disorder with phenotypic variability
Marfan  Syndrome  (MFS)  is  an  autosomal  dominant  inherited  connective  tissue
disease with an estimated prevalence of 1/5,000 in the general population.1 It is a
disease with multi-system involvement and phenotypic variability. First described by
Antoine-Bernard Marfan in 1896, it is caused by a mutation in the FBN1 gene on
chromosome  15q21 encoding fibrillin-1.2,3 Fibrillin-1 is  a  large extracellular  matrix
glycoprotein  that  provides  elasticity  as  well  as  structural  integrity  to  connective
tissues. Although the typical  clinical  features involve cardiac, skeletal,  and ocular
systems, the main risk of morbidity and mortality in these patients is attributed to the
development  of  aortopathy  and  subsequent  aortic  dissection.  Aneurysm  of  the
ascending  aorta  was  first  described  by  Taussig  and  colleagues  in  1943.4 Aortic
dissection  often  presents  acutely  with  a  high  risk  of  mortality  and is  not  always
preceded by chronic symptoms. For this reason, the current European Society of
Cardiology  (ESC)  guidelines  for  the  management  of  grown-up  congenital  heart
disease recommends yearly echo surveillance.5 Aortic root surgery is recommended
once the maximal aortic root diameter reaches ≥ 45 mm in those who are at high
risk.5 The average life expectancy for patients with MFS is estimated to be around 41
years.6
Fibrillin-1 and the role of TGF-ß
The connective tissue disorder  seen in  MFS is  caused by mutations in  fibrillin-1
which  is  encoded by  the  FBN1 gene.7 Fibrillin-1  is  a  350kD glycoprotein  that  is
synthesized  as  a  375  kD  precursor  and  is  processed  and  secreted  into  the
extracellular  matrix  (ECM).8 Fibrillin  monomers  polymerise  into  microfibrils  that
incorporate other proteins, for example latent transforming growth factor ß-binding
proteins  (LTBPs).8 This  fibrillin-LTBPs complex  binds TGF-ß in  an  inactive  state.
Mutations  in  fibrillin-1  therefore  disrupts  the  relationship  between  fibrillin-1  and
LTBPs.  The  result  is  diminished  sequestration  of  latent  TGF-ß  in  the  ECM and
subsequent excess TGF-ß signalling.7 It has been shown that excess signalling and
altered TGF-ß activation lead to the pathological changes in the aorta and aortic root
dilatation seen in MFS. This concept has been demonstrated in animal models and
more  importantly,  the  administration  of  TGF-ß  neutralising  antibodies  prevented
these changes.9 It has formed the basis of our understanding of MFS and led to the
development  of  clinical  trials  utilising  angiotensin-receptor  blockers  and  beta-
blockers in treating patients with MFS.10-15  
Clinical utilities of biomarkers in MFS – the rationale for a biomarker
Despite  echo-based  surveillance  being  the  current  mainstay  of  management,
challenges remain. Firstly, echo surveillance is operator and patient dependent.16  A
larger body habitus attenuates ultrasound waveforms and often reduces the quality
of images obtained, resulting in reduced accuracy of any subsequent measurements
obtained. A more experienced operator is also more likely to obtain better images for
analysis.  Although  cross-sectional  imaging  such  as  computed  tomography  (CT)
offers  higher  resolution  images  and  therefore  more  accurate  measurements,  it
utilises more radiation and therefore is unsuitable for regular use in MFS patients
who are predominantly young individuals requiring prolonged periods of surveillance.
Secondly, aortic dissection can still occur in between scheduled surveillance scans
due to the highly variable onset and rate of aortic dilatation.17 For example, a period
of quiescent growth for many years can be followed by a period of rapid growth
within a short space of time. Thirdly, it is noteworthy that aortic dissection can still
occur below the surgical threshold. In a published series of 524 MFS patients, 158
patients had aortic dissection and 46% of these were below the surgical threshold.4
This suggests imaging-based surveillance alone in a disease which has a variable
rate  of  progression  is  an  unreliable  predictor  of  risk  of  dissection  and  may  not
accurately reflect the degree of disease severity.18 
Due to this, there has been recent interest in the role of biomarkers as potential
adjuncts to imaging in order to improve risk stratification and predict the course of
the  disease.  For  example,  augmentation  index  –  a  marker  of  arterial  stiffness
measured  non-invasively  by  applanation  tonometry  –  has  been  shown  to
independently  predict  progression of  aortic  root  disease.19-21 Similarly,  the role  of
circulating biomarkers to predict rate of aortic dilatation and improve risk stratification
has been explored. In a disease such as MFS where there is a highly variable age of
onset,  phenotype,  and rate  of  aortic  dilatation,  a  biomarker  with  good predictive
value could potentially be useful. Moreover, not all FBN1 gene mutations lead to a
diagnosis  of  MFS.2 Although  the  study  of  biomarkers  in  MFS is  not  an  entirely
evidence-free zone, to our knowledge there has been very limited previous work on
circulating biomarkers in this patient group apart from studies on TGF-. Crucially, no
biomarker has made the successful transition into routine clinical use. This is likely
due  to  the  inherent  challenges  of  an  ideal  biomarker,  which  ideally  should  be
pathologically  relevant,  measurable,  has  prognostic  value  or  able  to  measure
response  to  therapy.  In  this  review,  we  summarise  previously  studied  plasma
biomarkers (Table 1) in particular TGF- as well as other potential biomarkers that
have  been  studied  in  other  forms of  aortopathies  (Table  2)  and  therefore  might
potentially prove useful in MFS.
Biomarker candidates in MFS – circulating biomarkers
1. TGF- 
Due to the central role that excess TGF- signalling plays in MFS, it is unsurprising
that there has been great interest in its potential role as a plasma biomarker and it
remains  the  most  studied  out  of  all  potential  biomarkers.  In  a  study of  99  MFS
patients, Lutter at al demonstrated significantly higher circulating plasma levels of
TGF- in  MFS  patients  compared  to  healthy  controls  (109  pg/ml  vs  54  pg/ml,
p<0.001).22 A higher plasma TGF- level was also modestly correlated with larger
aortic root dimensions measured on magnetic resonance imaging (MRI) (r = 0.26,
p=0.027),  previous aortic  root  surgery  and faster  aortic  root  growth  rate  (r=0.42,
p<0.001).22 The optimal cut-off value was 140 pg/ml (AUC 0.71, 95% CI 0.58 to 0.84,
p = 0.006) for the composite clinical endpoint of aortic dissection and prophylactic
aortic root replacement. Patients with plasma TGF- levels beyond this threshold
were 6.5 times more likely to experience the composite endpoint.22
This finding echoes earlier findings in murine models which have been validated in
human MFS subjects. Circulating plasma TGF-1 levels were observed to be higher
in 16 MFS mutant mice (Fbn1C1039G/+) compared to wild-type mice (115 ± 8 ng/mL
versus 92 ± 4 ng/mL, p=0.01).23 Correlation was seen between circulating free TGF-
1 levels and aortic root diameters at the level of Sinus of Valsalva (r=0.6, p<0.001).
In human subjects, TGF-1 was also seen to be significantly elevated in patients
with MFS (n=53) compared to controls (15 ± 1.7 ng/mL versus 2.5 ± 0.4 ng/mL,
p<0.0001).23 It is noteworthy that circulating TGF-1 levels were seen to decrease
after the administration of losartan and ß-blocker therapy, reflecting the benefit of
blunting excessive TGF-ß activation.23 
Despite this, it is recognised that TGF- response to angiotensin receptor blockers
can be varied. In a sub-study of an open-label randomised controlled trial comparing
losartan to standard therapy (COMPARE trial), the investigators reported only a third
of patients had a reduction in TGF- despite having a reduction in aortic dilatation
rate (AoDR).24,25 Patients who demonstrated a reduction in TGF- levels following
losartan  therapy  had  higher  baseline  plasma  TGF- and  a  higher  AoDR.24 This
suggests TGF- levels are probably markers of aortic disease severity rather than
initiators  of  aortic  dilatation.24 Variability  of  TGF- levels  following  therapy  raises
uncertainty with regards to its value in monitoring treatment response.
In addition, not all studies show increased levels of TGF- in MFS patients. Ogawa
and colleagues did not find a significant difference in TGF-1 levels in a cohort of
Japanese MFS patients compared to controls.26 This finding is different to that of
earlier studies of TGF-. Although this alone does not eliminate the possibility of its
role in MFS pathogenesis, it is possible that there are ethnic and genetic differences
affecting levels of TGF- in MFS as the majority of earlier studies were conducted in
white European/north American cohorts. 
Therefore TGF- remains a potential biomarker and has not yet made the successful
transition into  routine clinical  practice.   A few possible  explanations exist.  Firstly,
there is a huge number of possible FBN1 mutations. The most recent update lists
3077 possible mutations.27 Depending on the underlying mutation, either a dominant
negative or haploinsufficient effect will be seen and will affect the amount of TGF-
released from the fibrillin-1 network.24 Secondly, there is a variation in the abundance
of angiotensin type 1-receptor (AT-1) expression. Finally polymorphism in the renin-
angiotensin-aldosterone system (RAAS) could also affect TGF- response.24 
2. Fibrillin-1 fragments
FBN-1 mutations lead to instability in the fibrillin-1 protein and therefore increases its
susceptibility to proteolytic degradation.28 Marshall and colleagues hypothesized that
proteolytic  degradation  releases  fragments  of  fibrillin-1  and  other  elastic  fibre
proteins into the circulation and can therefore be used as a potential  biomarker,
specifically as a predictive tool for risk of aortic dissection in MFS and other thoracic
aortic aneurysms (TAA).28 In a study of 1265 patients from a registry cohort, 118 of
whom had a confirmed or suspected diagnosis of MFS, plasma levels of fibrillin-1,
fibrillin-2  and  fibulin-4  were  measured  and  compared  to  controls.  A significantly
higher proportion of patients with TAA had detectable fibrillin-1 fragments. Acute or
subacute  aortic  dissection  were  associated  with  fibrillin-1  levels  in  the  highest
quartile, compared to patients with no dissection or those with chronic dissection.28
These associations were not seen with fibrillin-2 or fibulin-4. 
In  addition,  fibrillin-1  levels  were  significantly  associated  with  aortic  aneurysm
location.  Patients  with  TAA demonstrated  higher  levels  of  measurable  fibrillin-1
segments compared to those with abdominal aortic aneurysm (AAA).28 Based on this
early  work,  further  longitudinal  studies  to  assess  the  relationship  of  circulating
fibrillin-1 levels and long-term rate of aortic dilatation rate are ongoing. 
3. Homocysteine Y (tHCy)
The large variation  in  cardiovascular  manifestations among MFS patients  is  well
recognised.  Giusti  et  al  sought  to  explain  this  observation  by  exploring  the  role
played  by  homocysteinaemia  and  the  prevalence  of  the  C677T
methylenetetrahydrofolatereductase (MTHFR)  polymorphism.29 Plasma
homocysteine has previously been shown to correlate significantly with the degree of
atherosclerosis  in  the  thoracic  aorta.30 Furthermore,  higher  levels  of  plasma
homocysteine  Y (tHCy)  were  also  shown to  be  associated  with  a  higher  risk  of
requiring  AAA surgery,  suggesting a potential  role  played by  tHCy in  endothelial
disruption.2 
Giusti and colleagues therefore explored whether this same relationship existed in
MFS patients. 107 MFS patients were divided into 3 groups based on whether they
had no cardiovascular manifestations, mild cardiovascular manifestations (defined as
aortic  root  dilatation  <  2.2  cm/m2 body  surface  area)  or  major  cardiovascular
manifestations  (aortic  root  dilatation  >  2.2  cm/m2 body  surface  area).  Following
multivariate  logistic  regression  analysis,  the  authors  concluded  that  there  was  a
significantly  higher  level  of  plasma  tHCy  in  MFS  patients  with  more  severe
cardiovascular manifestations compared to those who do not. Interestingly, levels of
tHCY also  reflected  disease  acuity  as  within  this  same  group  those  with  aortic
dissection  had  the  highest  level  of  tHCy.  This  could  potentially  be  explained  by
increased elastolysis via MMP activation that is induced by hyperhomocysteinaemia
as  shown  in  previous  studies.31,32 Large,  prospective  studies  with  hard  clinical
outcomes or long-term follow-up are lacking and therefore its real world clinical utility
remains unclear. 
4. Matrix metalloproteinase (MMP) 
Matrix  metalloproteinases  are  endopeptidases  which  play  a  key  role  in  the
elastolysis of the ECM in MFS. It has been established in previous studies that the
process  of  medial  degeneration  in  thoracic  aortic  aneurysm  of  MFS  patients  is
facilitated  by  the  increased  levels  of  MMP activity.33 In  addition  to  cystic  medial
necrosis (CMN), immunohistochemistry of tissue samples from MFS patients with
aortic  aneurysm  have  shown  strong  immunoreactivity  for  all  MMP subtypes,  in
particular MMP-2 and MMP-9.33,34 Upregulation of MMP-2 and MMP-9 activity result
in loss of elastic fibre integrity and reduction of vascular smooth muscle (VSMC)
contraction.34,35 In mice models of MFS, deletion of MMP-2 inhibited TGF- activation
and phosphorylation  of  Erk1/2  and Smad2 resulting  in  prolonged lifespan of  the
mice.34
Although the role of MMP as a plasma biomarker in MFS has not been studied, it
has been studied in patients with bicuspid aortic valve (BAV) aortopathy. BAV has
similarities with MFS with regards to deficiency in fibrillin-1 content within the aortic
wall as demonstrated by Fedak and colleagues in a study of 16 BAV patients where
fibrillin-1  content  within  the  aortic  tissue  of  BAV  patients  were  found  to  be
significantly less than in patients with tricuspid aortic valves.36 
Studies of MMP in BAV patients have demonstrated increased levels of circulating
MMP  particularly  MMP-2  and  MMP-9,  however  the  relationship  with  tissue
expression of MMP has been less certain. In a study of 29 patients with ascending
aortic aneurysms, 14 of whom had BAV, LeMaire et al. demonstrated normal tissue
MMP-9 expression in patients with BAV-associated aortopathy, a finding that was
different  to  Boyum  et  al.  who  showed  significantly  increased  tissue  MMP-9
concentrations in patients with BAV aortopathy.37,38 This reflects the heterogeneity in
phenotype seen in BAV, a feature that is also more prevalent in MFS. The majority of
studies of MMP levels in BAV patients have focused on its correlation with aortic root
size and although this has been shown, there has been no study so far that has
demonstrated its prognostic predictive value for adverse events.39 
What is clear however, higher levels of MMP-2 in patients with BAV and a dilated
proximal aorta has been associated with endothelial dysfunction and increased aortic
stiffness compared to those without proximal aortic dilatation.40 These are positive
early findings in the BAV cohort, and they have not been extensively studied in MFS
patients.  
5. Lysyl oxidase 
Elastin provides structural integrity to the ECM and elasticity for arterial structures
such as the aorta. Mature elastin is formed from precursor tropoelastin molecules
which are linked via their lysine residues with desmosine and isodesmosine cross-
links. This process is catalysed by lysyl oxidase which is an extracellular, copper-
containing  enzyme.41 It  is  encoded by  the  LOX gene and inactivation  has  been
shown to cause structural alteration in abdominal arterial walls.41,42 Therefore, high
levels of LOX gene expression may stabilise an aneurysm, and LOX isoforms are
measurable in serum samples.2 However, these studies have been based on murine
models of AAA as well as other diseases such as systemic sclerosis and certain
types of tumours. Its role as a biomarker in human MFS has not yet been studied
and is therefore unclear.41,42 
6. Tissue inhibitor of MMP (TIMP)
Previous immunohistochemistry studies of tissue samples from patients with MFS
have  demonstrated  cystic  medial  necrosis  and  loss  of  elastic  fibres  but  more
importantly  also  demonstrated  increased  levels  of  expression  of  MMPs  without
corresponding increase in  TIMPs.  This  imbalance of  activity  between MMPs and
their endogenous inhibitors - tissue inhibitor of MMP (TIMP) - has been implicated in
the  development  of  aortic  root  dilatation  seen  in  MFS.43,44 Studies  exploring  its
potential use as a biomarker however are limited. 
7. Collagen and elastin markers
Markers of elastin and collagen degradation have been studied in AAA patients but
not in patients with MFS. However, it is possible that similar findings will be present
in MFS and patients with TAA due to the role of elastin degradation in aneurysm
dilatation and collagen breakdown leading to rupture. In a study of 87 patients with
AAA, serum propeptide of type III procollagen (PIIINP), a marker of type III collagen
turnover was found to be higher than in control subjects (3.47 μg/L vs 2.73 μg/L,
p<0.0001).45 There  was  only  a  weak  correlation  with  AAA diameter  (r  =  0.27,
p=0.04).45 
Elastin  turnover  and collagen degradation might  also affect  aortic  distensibility,  a
factor that may predict  aortic aneurysm growth and rupture. This hypothesis was
explored  by  Wilson  et  al.  by  measuring  serum  elastin  peptides  (SEP),  plasma
elastin-α1-antitrypsin complex (E-AT), and PIIINP; all markers of serum elastin and
collagen  metabolism.  These  were  compared  to  aortic  distensibility  measured  on
ultrasound by means of pressure-strain elastin modulus (Ep) and stiffness.46 Aortic
wall distensibility was associated with increased elastin turnover but was inversely
related with collagen turnover.46 This suggests that an aortic aneurysm becomes less
compliant and less able to cope with haemodynamic stress as it grows and loses
increasing amounts of collagen. 
8. Genetic biomarkers
The potential  use of genetic sequencing to  identify  common loci  associated with
familial  TAA in  MFS and  use  it  as  a  biomarker  is  enticing.   Recent  work  have
identified the potential of utilising non coding micro-RNA as a potential therapeutic or
biomarker target.47 The technology however is still developing and it remains to be
seen if this will be translated into clinical practice.47 In addition, genetic biomarkers
are unlikely to be able to monitor disease progression due to the fixed nature of the
genomic code. It is also common to find a similar genetic variant among different
types of  hereditary TAA, rendering this  method less specific  for  MFS. Costs are
potentially a barrier to widespread clinical use. 
Biomarker candidates in MFS – imaging biomarkers
Apart  from  the  aforementioned  potential  circulating  biomarkers,  there  has  been
previous  work  on  imaging  biomarkers,  albeit  limited.  In  this  regard,  magnetic
resonance imaging  (MRI)  is  the  most  studied  modality  as  a  potential  adjunct  to
echocardiography. 
The role of MRI as a potential prognostic imaging biomarker has been explored by
Morris et  al.  who demonstrated that  increased vertebral  tortuosity  index (VTI)  as
measured by magnetic resonance angiography (MRA) is a reproducible marker of
adverse cardiovascular outcomes in patients with connective tissue disorders.48 Their
analysis on patients with MFS and Loeys-Dietz Syndrome (LDS) revealed a higher
risk of earlier surgery for those patients with a higher VTI compared to controls, after
adjusting for aortic root size.48 There was no significant correlation between VTI and
change in aortic z-score over time.48 Vertebral tortuosity was a common finding in
MFS patients, reflecting multi-system involvement beyond aortic root and proximal
ascending  aorta.  The  authors  hypothesised  that  vascular  fragility  as  a  result  of
defective fibrillin-1 manifests itself as tortuosity in the thin-walled vertebral arteries,
although this has not yet been proven.48 
Similarly, a higher aortic tortuosity index (ATI) obtained by MRI has been shown by
Franken et al. to be associated with a more severe MFS aortic phenotype and an
increased  risk  of  developing  an  aortic  dissection.49 However,  to  the  best  of  our
knowledge none of these imaging techniques have made it into routine clinical use
as a prognostic biomarker or to monitor therapy. 
Future perspectives
The inability of previously studied biomarkers to make the transition to routine clinical
use  creates  an  unmet  clinical  need  in  this  area.  Phenotype  heterogeneity  in
congenital  heart  disease  such  as  MFS  makes  finding  a  pathologically  relevant
plasma  biomarker  challenging.  MFS  aortopathy  is  understood  to  involve  many
different  complex  mechanisms,  as  discussed  previously  and  an  ideal  plasma
biomarker  should  be  measurable,  reliable,  and  more  importantly  pathologically
relevant. There is currently a lack of prospective studies or large MFS registries to
test the clinical utility of potential biomarkers. 
Recently,  there  has  been  interest  in  newer  biomarker  candidates.  In  particular,
biomarkers  that  reflect  the  process  of  elastin  degradation  which  is  a  common
pathway shared by all forms of aortopathies. In this regard, the role of desmosine
which  is  a  specific  elastin-degradation product  has been explored as a potential
biomarker in AAA and MFS. Early work on a cohort of MFS patients have yielded
encouraging results.50 Plasma and  urinary  desmosine  were  significantly  elevated
compared to age and gender-matched controls.50 Urinary desmosine (uDES) also
showed a strong correlation with aortic root size (r=0.79, p=0.04).50 Further work is
therefore  needed in  this  area utilising  larger  cohorts  of  patients  to  determine its
prognostic value. 
Conclusion
With advances in care for patients with adult congenital heart disease (ACHD), the
majority of patients are surviving well into adulthood. Mortality in patients with MFS
remains high and aortic dissection resulting from aortopathies remain the biggest
contributing factor. Biomarkers have a potential adjunctive role to play, in monitoring
disease progression as well as identifying those at greatest risk of adverse events.
TGF- remains the most studied out of all the potential biomarkers, however none
have made the successful transition into routine clinical practice. This is likely due to
the  inherent  challenges  of  identifying  an  ideal  biomarker,  requiring  it  to  be
pathologically  relevant,  has  prognostic  value,  or  able  to  monitor  response  to
treatment. Newer biomarker candidates therefore have a significant role to play and
further work is needed in this area of unmet clinical need.
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Biomarker Key findings Proposed utilities Original publication
TGF- ß Plasma TGF- ß correlates with  larger  aortic  root
diameters,  faster  aortic  root  growth  and  earlier
aortic root surgery for levels > 140 pg/mL
Predictor  for  aortic  root  size,
rate  of  growth  and
cardiovascular events
Franken et al22
Total serum TGF- ß1 is increased in patients with
MFS with causative FBN1 mutations
Hillebrand et al51, Matt et al23
Losartan responders had higher baseline plasma
TGF- levels
Franken et al24
Plasma TGF- ß levels were significantly higher in
MFS patients with aortic root dilatation compared
to those without
Radonic et al52
No significant difference in plasma TGF-β1 levels
between MFS patients and controls in a Japanese
population
Ogawa et al26 
TGF-β1  expression  in  peripheral  blood  and
aneurysmal  aortic  tissues  was  significantly
elevated in MFS patients
Kim et al53
Fibrillin-1 Circulating  fibrillin-1  fragments  were  higher  in
patients with TAA 




tHcy  levels  were  significantly  higher  in  patients
with more severe cardiovascular manifestations of
MFS and  aortic  dissection  compared  to  patients
with milder phenotypes and no aortic dissection
Marker of disease severity Giusti et al54
TIMP Imbalance between MMP and TIMP activity in MFS
subjects
Mechanistic explanation for 
ECM remodelling seen in 
MFS. Potential therapeutic 
target.
Williams et al43 Ikonomidis44
ECM, extracellular matrix; FBN1, fibrillin-1; MFS, Marfan Syndrome; MMP, matrix metalloproteinase; TAA, thoracic aortic aneurysm; TGF- ß, transforming growth 
factor beta; tHCY; total homocysteine; TIMP, tissue inhibitor of metalloproteinase
Table 1 - Previously studied plasma biomarkers of aortopathy in MFS 
Biomarker Key findings Proposed utilities Original publication
MMP Higher  circulating  levels  of  MMP,
particularly MMP-2 and MMP-9 have
been demonstrated in multiple BAV
cohorts 
Marker of aortic dilatation Drapisz et al55, Wang et
al39,  LeMaire  et  al38,
Tzemos  et  al40,
Ikonomidis  et  al56,
Boyum et al37
Lysyl oxidase Encoded by LOX gene, high level of
gene expression stabilises AAA
Therapeutic use of overexpression of 
LOX/LOXL enzymes to stabilize AAA
Joni  et  al41,  Remus  et
al42, Pepe et al2
Serum propeptide of 
type III procollagen 
(PIIINP)
Serum PIIINP higher in AAA patients
than in controls
Marker of aortic dilatation Satta et al45
Serum  elastin  peptides
(SEP),  plasma  elastin-
α1-antitrypsin  complex
(E-AT)
Both  SEP  and  plasma  E-AT
correlated  with  higher  elastin
turnover  and  decreased  aortic
compliance
Predictor of rupture Wilson et al.46
AAA, abdominal aortic aneurysm; BAV, bicuspid aortic valve; E-AT, plasma elastin-α1-antitrypsin complex; LOX, lysyl oxidase; LOXL, lysyl oxidase homolog; MMP, 
matrix metalloproteinase; PIIINP, serum propeptide of type III procollagen; SEP, serum elastin peptides; 
Table 2 - Previously studied plasma biomarkers of aortopathies not related to MFS with potential use in MFS
